Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1254 daily bars · split adjusted
Current price $5.46
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 7, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 6, 23 | EF Hutton | maintain | Hold | Hold |
| Jun 4, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 16, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 15, 23 | EF Hutton | maintain | Hold | Hold |
| Apr 3, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 31, 23 | EF Hutton |
Daily · Wilder smoothing
| Hold |
| Hold |
| Jan 5, 23 | EF Hutton | maintain | Hold | Hold |
| Sep 12, 22 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 40.73 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 7.83 | Oscillator | Buy |
| Williams %R (14) | -91.89 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.31 (Hist -0.08) | Oscillator | Strong Sell |
| Average Directional Index (14) | 12.19 (+DI 24.0 / -DI 25.3) | Trend | Neutral |
| EMA 20 | 6.46 | MA | Strong Sell |
| SMA 20 | 6.41 | MA | Strong Sell |
| EMA 50 | 7.05 | MA | Strong Sell |
| SMA 50 | 6.93 | MA | Strong Sell |
| SMA 200 | 10.04 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | GTBP | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.1x | -17.3x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.5x | EPS est. -10.75 | Elevated |
| Price / Book | 2.4x | 37.7x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.1x | -16.7x | Discount |
| Return on equity | -443.1% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | 0.00 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -185.90 | Distress |
Discounted cash flow model
Stock news · updated daily
FDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026 Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway into Q3 2027 SAN FRANCISCO, CALIFORNIA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced IND clearance from the FDA for GTB-5550 in multiple myeloma.
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 4, 25 | Mun-Gavin David C. | director | A-Award | 31,250 @ $1.33 | $41.56K |
GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 14, 2026 | -2.00 | -3.00 | Miss -50.0% | — |
| May 21, 2026 | -2.00 | -0.11 | Beat 94.5% | — |
| Mar 2, 2026 | -5.50 | -55.50 | Miss -909.1% | — |
| Nov 13, 2025 | -9.50 | -0.83 | Beat 91.3% | — |
| Aug 13, 2025 | -17.00 | -0.55 | Beat 96.8% | — |
| May 21, 2025 | -16.00 | -0.33 | Beat 97.9% | — |
| Sep 4, 25 |
| Breen Michael Martin |
| director, officer: CEO and Director |
| A-Award |
| 100,000 @ $1.33 |
| $133.0K |
| Sep 4, 25 | Urban Alan Louis | officer: Chief Financial Officer | A-Award | 50,000 @ $1.33 | $66.50K |
| Sep 4, 25 | Casamento Charles J | director | A-Award | 62,500 @ $1.33 | $83.13K |
| Sep 4, 25 | Kramer Hilary | director | A-Award | 31,250 @ $1.33 | $41.56K |
| Jun 10, 25 | Mun-Gavin David C. | director: | 0 | — |
| May 7, 25 | Kramer Hilary | director: | 0 | — |
| May 8, 25 | Ritter Andrew J | director: | 0 | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| EFFECT | Oct 20, 2026 | 2026-10-21 00:15:15 | View |
| 424B3 | Oct 20, 2026 | 2026-10-20 17:20:37 | View |
| DEF 14A | Oct 13, 2026 | 2026-10-13 17:00:12 | View |
| S-1 | Oct 9, 2026 | 2026-10-09 17:27:45 | View |
| PRE 14A | Oct 2, 2026 | 2026-10-02 17:26:38 | View |
| D | Sep 29, 2026 | 2026-09-29 13:06:17 | View |
| 8-K | Sep 25, 2026 | 2026-09-25 16:10:15 | View |
| 8-K | Sep 21, 2026 | 2026-09-21 16:10:24 | View |
| SC 13G | Sep 15, 2026 | 2026-09-15 19:35:02 | View |
| 8-K | Sep 15, 2026 | 2026-09-15 08:57:47 | View |
Proxy statement (DEF 14A) disclosures
